- Home
- KULR vs GLSI Comparison
KULR vs GLSI Comparison
Compare KULR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- GLSI
- Stock Information
- Founded
- KULR 2013
- GLSI 2006
- Country
- KULR United States
- GLSI United States
- Employees
- KULR N/A
- GLSI N/A
- Industry
- KULR Electrical Products
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- KULR Technology
- GLSI Health Care
- Exchange
- KULR Nasdaq
- GLSI Nasdaq
- Market Cap
- KULR 163.0M
- GLSI 145.2M
- IPO Year
- KULR N/A
- GLSI 2020
- Fundamental
- Price
- KULR $3.12
- GLSI $8.70
- Analyst Decision
- KULR Strong Buy
- GLSI Strong Buy
- Analyst Count
- KULR 2
- GLSI 1
- Target Price
- KULR $40.00
- GLSI $39.00
- AVG Volume (30 Days)
- KULR 2.2M
- GLSI 79.8K
- Earning Date
- KULR 11-13-2025
- GLSI 11-14-2025
- Dividend Yield
- KULR N/A
- GLSI N/A
- EPS Growth
- KULR N/A
- GLSI N/A
- EPS
- KULR N/A
- GLSI N/A
- Revenue
- KULR $12,977,975.00
- GLSI N/A
- Revenue This Year
- KULR $27.50
- GLSI N/A
- Revenue Next Year
- KULR $164.50
- GLSI N/A
- P/E Ratio
- KULR N/A
- GLSI N/A
- Revenue Growth
- KULR 35.81
- GLSI N/A
- 52 Week Low
- KULR $2.44
- GLSI $7.88
- 52 Week High
- KULR $43.92
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- KULR 30.70
- GLSI 38.48
- Support Level
- KULR $3.88
- GLSI $8.02
- Resistance Level
- KULR $4.35
- GLSI $9.51
- Average True Range (ATR)
- KULR 0.23
- GLSI 0.57
- MACD
- KULR -0.10
- GLSI -0.06
- Stochastic Oscillator
- KULR 17.48
- GLSI 31.88
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.